Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from EDIT

RFK Jr. Just Supercharged These 2 Biotech Penny Stocks

SGMO and EDIT are set to benefit from RFK Jr.’s plans to fast-track the review of drugs targeting rare diseases.

Editing More than Spaces: How EDIT Design House Built a Business on Telling Stories Through Interiors

Editing More than Spaces: How EDIT Design House Built a Business on Telling Stories Through Interiors

An elevated philosophy, design as personal evolution, is what sets EDIT Design House apart in a crowded market. The team doesn't just create beautiful rooms; they curate experiences and identities.

International Business Times

1 Penny Stock to Grab Now for 183% Upside Potential

1 Penny Stock to Grab Now for 183% Upside Potential

This biotech penny stock could more than triple, based on consensus forecasts.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Brand Impact Awards 2024: all the winners revealed

Explore all the winners at the 11th-annual BIAs – including our two Best of Show awards

Porsche 911 997 Restomod Created By Edit Automotive Starts At $184,450

The company plans to build 99 cars which it says produce a pure connection between driver and machine.

New fine-dining vegan restaurant Edit is launching in Hackney

The January opening will offer a six-course tasting menu

Evening Standard

4 Genomics Stocks to Consider Buying After the Crash

The genomics industry is poised to grow significantly in 2022, driven by strong demand amid the increasing need for personalized medicine and the rising population with serious illnesses. Thus, beaten-down genomics stocks Invitae (NVTA), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP) could be ideal investments now.

inkl

Read news from The Economist, FT, and more,
with one subscription

Editas Medicine's Return On Capital Employed Insights

Editas Medicine's Return On Capital Employed Insights

Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.

Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know

Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know

Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to access the live webcast.

Twitter launching edit button would be a ‘mistake’, former executive warns

Twitter launching edit button would be a ‘mistake’, former executive warns

The social media giant has confirmed it will begin testing the function in the coming months.

The Independent UK

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The decision is part of a long-running legal battle brought by two universities and one of the founders of the gene-editing technique Emmanuelle…

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

Here's a roundup of top developments in the biotech space over the last 24 hours:

Editas Suddenly Terminates Chief Medical Officer Without An Explanation

Editas Suddenly Terminates Chief Medical Officer Without An Explanation

Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company.

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Harvard University

National Portrait Gallery

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

302,804 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play